The HemosIL AcuStar recall is a useful case study in how a small, systematic bias in a laboratory assay can matter clinically. On 30 October 2026 the US Food and Drug Administration (FDA) published an early alert for certain lots of the HemosIL AcuStar HIT-IgG(PF4-H) test, made by Instrumentation Laboratory (Werfen), and the FDA describes the event as the most serious type of recall. The concern is false-negative results for antibodies linked to heparin-induced thrombocytopenia (HIT). This article takes an evidence-focused look at the problem. It is news reporting and not medical advice.
HemosIL AcuStar recall: key takeaways
- Customers reported invalid calibration curves, and Werfen confirmed a negative bias of 20% to 35% in the affected lots.
- Results can fall below the 1.00 U/mL cut-off and be reported as negative when HIT antibodies are present.
- Routine calibration and quality control may not reliably detect the problem, according to the FDA.
- As of 3 September 2026, Werfen reported no serious injuries or deaths.
- The root cause is still under investigation.
The science behind the HemosIL AcuStar recall
HIT is an immune reaction in which antibodies bind a complex of platelet factor 4 and heparin, activate platelets and can cause a fall in platelet count together with a risk of clots. Laboratories detect these antibodies with immunoassays. The HemosIL AcuStar test is a quantitative assay with a cut-off of 1.00 U/mL, so results below that line are reported as negative. Because the decision rests on a threshold, a shift in the measured value can change the reported category without anything else changing.
How a bias can create false negatives in the HemosIL AcuStar recall
Here is an illustration of our own, not a figure from the recall. If a patient’s true value were 1.40 U/mL and the assay read 30% low, the reported value would be about 0.98 U/mL, just under the cut-off, and the result would be reported as negative. Results far above the threshold would stay positive, while those near it are most exposed. The reported biases of 20% to 35%, and one complaint of 47%, therefore put borderline results at the greatest risk. This is a simplified model and real assays have additional variation.
Why quality control may miss the HemosIL AcuStar recall problem
Quality control samples check that an assay performs within limits at set concentrations. The FDA notes that routine calibration and quality control may not reliably detect this fault. One possible reason, which is our inference and not a finding, is that the problem may affect patient samples differently from control materials. The company said the root cause was under investigation, so no explanation has been confirmed.
Clinical context for the HemosIL AcuStar recall
A false-negative antibody result may delay recognition of HIT, and continued heparin exposure may raise the risk of clots, according to the FDA. In practice, clinicians weigh the pre-test probability, platelet trends and timing of heparin exposure alongside laboratory results, and some laboratories confirm with a functional assay. Those are general background points. The FDA leaves decisions on reviewing past results to laboratories and clinicians. The agency’s notice is at fda.gov.
Lots and uncertainty in the HemosIL AcuStar recall
The FDA early alert lists four lots: B40005 and B38062 for part 0009800127, and B40006 and B38063 for part 0009802028. The database entry lists only two lots and says an expanded notice on 29 September 2026 added more. This is a discrepancy between sources, so laboratories should confirm against Werfen’s notice. The database records 434 units in commerce. The product also went to about 23 other countries including Germany, Japan, the UK and India.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Hematology Diagnostics Market report values the global market at USD 8.6 billion in 2024 and projects USD 15.2 billion by 2033, a CAGR of 6.7% for 2025 to 2033, with North America at about USD 3.78 billion, roughly 44% by our own calculation. Coagulation testing is not a listed segment, so the report does not size HIT assays. The page shows a 2022 update date against 2024 data, so use it as indicative.
Questions clinicians and laboratories may ask about the HemosIL AcuStar recall
Were any patients tested with affected lots? Can past results near the cut-off be reviewed? Which alternative assays are available, and how do they compare? The sources do not answer these. Adverse events can be reported to FDA MedWatch. See our medical device coverage.
Timeline of the HemosIL AcuStar recall
- 3 September 2026: recall initiated.
- 29 September 2026: expanded notice.
- 10 October 2026: FDA database entry posted.
- 30 October 2026: FDA early alert published.
General background: how diagnostic recalls are classified
The FDA uses Class I for situations where there is a reasonable chance that a product will cause serious harm or death. Classification reflects potential risk, not confirmed harm.
Our analysis of the HemosIL AcuStar recall
In our assessment, the HemosIL AcuStar recall is concerning mainly because the error is directional and may escape routine checks. The absence of reported serious injuries by early September is encouraging but cannot be taken as proof of safety.
What is not disclosed about the HemosIL AcuStar recall
- The root cause.
- Whether past results were affected in practice.
- The full expanded lot list.
Risks and caveats
This article relies on FDA pages and the company notice as summarised by the FDA. Our illustration of bias is simplified. Nothing here is medical advice.
What to watch next
- Root-cause findings.
- Updates to the lot list.
- Supply of replacement tests.
FAQ
What is the HemosIL AcuStar recall?
A Class I recall of certain lots of a HIT antibody test that may read too low.
Why can quality control miss it?
The FDA says routine calibration and quality control may not reliably detect the bias.
Were injuries reported?
As of 3 September 2026, none serious, per Werfen.
How we reported this: we relied on the FDA early alert and recall database entry, public regulator pages and the Acumen Research and Consulting report cited above. Our calculations and illustrations are labelled. Last updated 2 November 2026. This is news reporting and not advice.
